(Boston, MA): The Neuroendocrine Tumor Research Foundation (NETRF) is proud to join Chimeric Therapeutics in announcing that CAR T-cell therapy using CHM CDH17 has been

In a breakthrough for those with advanced pheochromocytoma and paraganglioma (Pheo/Para), the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan) as a treatment

Patient enrollment has begun at a fourth site for the world’s first CAR T-cell therapy clinical trial for neuroendocrine cancer. Winship Cancer Center at Emory

A new global clinical trial is evaluating the investigational drug FORE8394 (plixorafenib) for treatment of neuroendocrine carcinomas with BRAF V600E-mutations. The phase 2 study aims

Neuroendocrine tumors (NETs) are complex cancers that can originate in various organs, including the ovaries. While primary ovarian NETs (PON) are uncommon, distinguishing them from

As the Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), I’ve dedicated my career to advancing science that gives patients and families more

The U.S. Food and Drug Administration (FDA) has approved cabozantinib for the treatment of previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors

Chimeric Therapeutics is reporting early signs of efficacy in the world’s first clinical trial of CAR T cell therapy for neuroendocrine cancer. The first NET

The investigational therapy ITM-11 has shown promising results in the Phase 3 COMPETE trial for patients with inoperable, progressive Grade 1 and Grade 2 gastroenteropancreatic

The U.S. Food and Drug Administration (FDA) has granted priority review to Merck’s application for WELIREG® (belzutifan) as a treatment for adult and pediatric patients